Agilon Health | AGL | Long at $2.24Agilon Health NYSE:AGL
Pros:
Revenue consistently grew from 2019 ($794 million) to 2023 ($4.3 billion) and through three quarters of 2024 ($5.6 billion). Expected to reach $8.7 billion by 2027.
Current debt-to-equity ratio 0.06 (very low)
Sufficient cash reserves to fund operations and strategic initiatives
Strong membership growth (525,000 as of Q3 2024, a 37% year-over-year increase)
Recent insider buying ($2 - $3) and awarding of options
Cons:
Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years
No dividend
Targets (into 2027):
$2.72
$4.00
$5.00
$7.00
$11.50
$16.00
